Evidence map
How much real research exists behind each compound. Most research peptides are studied mainly in animals; only a few have randomized trials in people. Grades come from PubMed study-type tags and ClinicalTrials.gov — they describe the evidence base, not whether something works or is safe.
| Compound | Evidence | Papers | RCTs | Human clinical | Animal / lab only | Reg. trials |
|---|---|---|---|---|---|---|
| Oxytocin Approved as a prescription drug (e | Strong | 15,057 | 1,225 | 1,706 | 6,980 | 935 |
| Semaglutide Approved as a prescription drug (Ozempic, Wegovy, Rybelsus) | Strong | 5,726 | 311 | 659 | 273 | 789 |
| Tirzepatide Approved as a prescription drug (Mounjaro, Zepbound) | Strong | 2,647 | 134 | 249 | 75 | 305 |
| LL-37 | Strong | 4,704 | 63 | 144 | 824 | 20 |
| NAD+ | Strong | 3,901 | 61 | 114 | 1,307 | 268 |
| GHRP-2 | Strong | 213 | 42 | 60 | 64 | 0 |
| Thymosin Alpha-1 Thymalfasin is approved as a drug in several countries outside the US (Zadaxin), not in the US | Strong | 622 | 39 | 71 | 185 | 66 |
| Sermorelin Was previously approved in the US (Geref) and later discontinued by its manufacturer | Strong | 370 | 34 | 66 | 133 | 27 |
| Hexarelin | Strong | 291 | 26 | 59 | 107 | 0 |
| Tesamorelin Approved as a prescription drug (Egrifta) for HIV-associated abdominal fat | Strong | 95 | 21 | 26 | 1 | 24 |
| GHRP-6 | Strong | 639 | 19 | 44 | 351 | 0 |
| SS-31 | Strong | 460 | 18 | 25 | 166 | 21 |
| Cagrilintide Investigational: studied mainly in combination with semaglutide, not approved | Strong | 103 | 15 | 15 | 5 | 44 |
| PT-141 Bremelanotide is approved as a prescription drug (Vyleesi) for a specific indication | Strong | 113 | 14 | 18 | 7 | 10 |
| Retatrutide Investigational: in late-stage clinical trials, not approved anywhere | Strong | 207 | 10 | 13 | 10 | 33 |
| DSIP | Strong | 462 | 6 | 23 | 322 | 1 |
| Kisspeptin-10 | Strong | 317 | 5 | 7 | 172 | 36 |
| Epitalon | Strong | 166 | 5 | 7 | 103 | 1 |
| MOTS-c | Strong | 265 | 4 | 9 | 54 | 5 |
| Bromantane | Strong | 62 | 4 | 9 | 41 | 0 |
| TB-500 | Strong | 630 | 3 | 9 | 216 | 18 |
| Selank | Moderate | 68 | 2 | 3 | 49 | 2 |
| Ipamorelin | Moderate | 51 | 2 | 3 | 20 | 3 |
| Semax | Moderate | 209 | 1 | 5 | 145 | 0 |
| Melanotan II | Moderate | 199 | 1 | 14 | 137 | 1 |
| GHK-Cu | Moderate | 150 | 1 | 3 | 29 | 4 |
| CJC-1295 (with DAC) | Moderate | 35 | 1 | 2 | 5 | 1 |
| BPC-157 | Weak | 222 | 0 | 2 | 103 | 4 |
| Noopept | Weak | 107 | 0 | 3 | 71 | 0 |
| Pinealon | Weak | 15 | 0 | 1 | 5 | 0 |
| CJC-1295 (no DAC) | Weak | 5 | 0 | 1 | 0 | 0 |
| KPV | Preclinical only | 103 | 0 | 0 | 45 | 0 |
| AOD-9604 | Preclinical only | 23 | 0 | 0 | 3 | 0 |
| Dihexa | Preclinical only | 18 | 0 | 0 | 4 | 0 |
| CJC-1295 + Ipamorelin | Preclinical only | 12 | 0 | 0 | 1 | 0 |
| 5-Amino-1MQ | Preclinical only | 3 | 0 | 0 | 0 | 0 |
Several randomized controlled trials in humans, often summarized by meta-analyses.
At least one randomized trial or a meaningful body of human studies, but not a deep trial base.
Only a handful of human studies (case reports, small or uncontrolled studies). No randomized trials.
Research is in animals or cells. Results in rats or cell cultures often do not carry over to people.
We found no indexed peer-reviewed research for this compound name.
Method: each compound has a hand-written PubMed query. We count randomized controlled trials and meta-analyses by publication type, human clinical studies by study design (trials, clinical and observational studies, case reports), and animal/lab-only work by MeSH tags. Strong = 3+ RCTs (or a meta-analysis and 2+ RCTs); Moderate = 1+ RCT or 10+ human clinical studies; Weak = any human clinical study; Preclinical = animal or lab research only. Research use only; not medical advice.